替夫还债3在线观看完整版中文电影,功夫熊猫动漫,火线追凶2全集

Ombitasvir

NMR下載 COA and HPLC MSDS下載
names：
Ombitasvir
CAS號：
1258226-87-7
MDL Number： MFCD28386270
MF(分子式)： C50H67N7O8 MW(分子量)： 894.11
EINECS: Reaxys Number:
Pubchem ID:54767916 Brand:BIOFOUNT

Ombitasvir(1258226-87-7)是吡咯烷，氨基甲酸酯，芳族酰胺和二肽的成員。Ombitasvir結(jié)合并阻斷NS5A蛋白的活性。這導(dǎo)致病毒RNA復(fù)制復(fù)合物的破壞，HCV RNA產(chǎn)生的阻斷和病毒復(fù)制的抑制。 NS5A是一種與鋅結(jié)合且富含脯氨酸的親水性磷蛋白，在HCV RNA復(fù)制中起關(guān)鍵作用。 HCV是屬于黃病毒科的小型帶包膜單鏈RNA病毒；

貨品編碼	規(guī)格	純度	價格 (￥)	現(xiàn)價(￥)	特價(￥)	庫存描述	數(shù)量	總計 (￥)
YZM000558-10mg	10mg	99.79%	￥ 1822.00	￥ 1822.00		2-3天	- +	￥ 0.00
YZM000558-5mg	5mg	99.79%	￥ 1072.50	￥ 1072.50		2-3天	- +	￥ 0.00

大包裝詢價提供各種包裝，敬請垂詢
收藏商品商品點評加入購物車立即購買

快速詢價

收起

你想詢價的產(chǎn)品

*產(chǎn)品名稱：

CAS號：

產(chǎn)品編號：

需求描述：

請準確填寫您的聯(lián)系方式，以便為您提供最好的服務(wù)。

*公司名稱：

*電子郵箱：

聯(lián)系人：

*電話：

*驗證碼：

詢價

中文別名	Ombitasvir(cas:1258226-87-7),ABT-267,ABT267,ABT 267
英文別名	Ombitasvir(cas:1258226-87-7),ABT-267,ABT267,ABT 267,Ombitasvir(ABT-267)
CAS號	1258226-87-7
Inchi	InChI=1S/C50H67N7O8/c1-30(2)42(53-48(62)64-8)46(60)55-28-10-12-40(55)44(58)51-35-20-14-32(15-21-35)38-26-27-39(57(38)37-24-18-34(19-25-37)50(5,6)7)33-16-22-36(23-17-33)52-45(59)41-13-11-29-56(41)47(61)43(31(3)4)54-49(63)65-9/h14-25,30-31,38-43H,10-13,26-29H2,1-9H3,(H,51,58)(H,52,59)(H,53,62)(H,54,63)/t38-,39-,40-,41-,42-,43-/m0/s1
InchiKey	PIDFDZJZLOTZTM-KHVQSSSXSA-N
分子式 Formula	C50H67N7O8
分子量 Molecular Weight	894.11
溶解度Solubility	生物體外In Vitro:DMSO溶解度≥ 33 mg/mL(36.91 mM)*"≥" means soluble可溶, but saturation unknown溶解度未知.
性狀	固體粉末,Power
儲藏條件 Storage conditions	-20°C 3 years年 4°C 2 years年 / In solvent溶液中:-80°C 6 months月 -20°C 1 month月

Ombitasvir(CAS:1258226-87-7)實驗注意事項：
1.實驗前需戴好防護眼鏡，穿戴防護服和口罩，佩戴手套，避免與皮膚接觸。
2.實驗過程中如遇到有毒或者刺激性物質(zhì)及有害物質(zhì)產(chǎn)生，必要時實驗操作需要手套箱內(nèi)完成以免對實驗人員造成傷害
3.實驗后產(chǎn)生的廢棄物需分類存儲，并交于專業(yè)生物廢氣物處理公司處理，以免造成環(huán)境污染Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.

Tag:Ombitasvir蒸汽壓,Ombitasvir合成,Ombitasvir標準,Ombitasvir應(yīng)用,Ombitasvir合成,Ombitasvir沸點,Ombitasvir閃點,Ombitasvir用途,Ombitasvir溶解度,Ombitasvir價格,Ombitasvir作用,Ombitasvir結(jié)構(gòu)式,Ombitasvir用處

產(chǎn)品說明	Ombitasvir(1258226-87-7) 是一種有效的HCV NS5A的抑制劑,Ombitasvir溶解度,OmbitasvirMSDS詳見主頁
Introduction	Ombitasvir(1258226-87-7) is a potent inhibitor of thehepatitis C virus protein NS5A。
Application1	Ombitasvir(1258226-87-7) is a potent inhibitor of thehepatitis C virus protein NS5A，withEC50s of 0.82 to 19.3 pM against HCV genotypes 1 to 5, and 366 pM against genotype 6a.
Application2
Application3

警示圖
危險性	warning
危險性警示	Not available
安全聲明	H303吞入可能有害+H313皮膚接觸可能有害+H2413吸入可能對身體有害
安全防護	P264處理后徹底清洗+P280戴防護手套/穿防護服/戴防護眼罩/戴防護面具+P305如果進入眼睛+P351用水小心沖洗幾分鐘+P338取出隱形眼鏡（如果有）并且易于操作,繼續(xù)沖洗+P337如果眼睛刺激持續(xù)+P2393獲得醫(yī)療建議/護理
備注	實驗過程中防止吸入、食入，做好安全防護

2017-07-01 Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use Drugs

2016-08-01 Metabolism and Disposition of Pan-Genotypic Inhibitor of Hepatitis C Virus NS5A Ombitasvir in Humans Drug metabolism and disposition: the biological fate of chemicals

2016-08-01 Ombitasvir/Paritaprevir/Ritonavir: A Review in Chronic HCV Genotype 4 Infection Drugs

2015-09-01 Interferon-free therapy for hepatitis C: The hurdles amid a golden era Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association

2015-05-01 Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection The Annals of pharmacotherapy

1.Clinical Pharmacokinetics of Ombitasvir Clinical Pharmacokinetics 2017
Abstract：Ombitasvir is a potent, nonstructural protein 5A inhibitor of the hepatitis C virus (HCV) that is used in combination with other direct-acting antivirals for the treatment of chronic HCV infection. Ombitasvir is predominantly metabolized by amide hydrolysis followed by oxidative metabolism and is a substrate of P-glycoprotein. Ombitasvir displays linear pharmacokinetics with minimal accumulation and is eliminated via metabolism and biliary excretion. A negligible amount of unchanged drug is excreted in urine. Exposures are comparable across Chinese, Japanese, and non-Asian subjects. The pharmacokinetic characteristics of ombitasvir are similar in healthy subjects and HCV-infected patients, and are not appreciably altered by hepatic or renal impairment. Results from several drug interaction studies demonstrated that ombitasvir has a low potential for drug interactions.
2.Ombitasvir/Paritaprevir/Ritonavir: A Review in Chronic HCV Genotype 4 Infection Drugs 2016
Abstract：A fixed-dose tablet comprising the NS5A inhibitor ombitasvir, the NS3/4A inhibitor paritaprevir and ritonavir (ombitasvir/paritaprevir/ritonavir) (Technivie®, Viekirax®) is available for use, in combination with ribavirin, for the treatment of chronic hepatitis C virus (HCV) genotype 4 infection. High sustained virological response rates at 12 weeks post-treatment (SVR12) were achieved in treatment-naive or -experienced patients with chronic HCV genotype 4 infection, including patients without cirrhosis who received ombitasvir plus paritaprevir and ritonavir in combination with ribavirin for 12 weeks (SVR12 100 %) (PEARL-I trial), patients with compensated cirrhosis who received ombitasvir/paritaprevir/ritonavir plus ribavirin for 12 or 16 weeks (SVR12 97 and 98 %) (AGATE-I trial) , or Egyptian patients without cirrhosis who received ombitasvir/paritaprevir/ritonavir plus ribavirin for 12 weeks (SVR12 94 %) or with compensated cirrhosis who received ombitasvir/paritaprevir/ritonavir plu s ribavirin for 12 or 24 weeks (SVR12 97 and 93 %) (AGATE-II trial). Ombitasvir/paritaprevir/ritonavir was generally well tolerated in patients with chronic HCV genotype 4 infection without cirrhosis or with compensated cirrhosis in clinical trials. There have been postmarketing reports of hepatic decompensation and hepatic failure, which mainly occurred in patients with advanced cirrhosis who received regimens containing ombitasvir/paritaprevir/ritonavir. In conclusion, ombitasvir/paritaprevir/ritonavir is a valuable option for use in patients with chronic HCV genotype 4 infection without cirrhosis or with compensated cirrhosis.

對不起，暫無產(chǎn)品評價！

MSDS

SDS 1.0 中文

展開

SDS 1.0 英文

展開